NCT05876065Recruiting
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
Efficacy and Safety of Capecitabine and Cyclophosphamide (XC) Versus Physician's Choice as Maintenance Therapy for Advanced Breast Cancer: a Randomized, Controlled, Open-label Clinical Trial
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- First submitted
- 14 May 2023
- Start date
- 1 Jun 2023
- Primary completion date
- Jun 2027
- Lead sponsor
- Wenjin Yin
- Diseases
- Metastatic breast cancer
- NCT number
- NCT05876065
What you commit to
- Study type: Interventional
- Planned participants: 86
- From 1 Jun 2023 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- during pregnancy and lactation
- Patients with central nervous system metastasis
Who the study is looking for
- Female, age≥18 years old
- ECOG≤2
- Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions
- HR+/HER2+ or HR-/HER2+ or HR-/HER2-
- At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1
- Disease control (complete response + partial response + stable disease) after salvage treatment
- Expected survival ≥6 months
- Adequate organ function
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiaotong University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.